A new mental health-driven biotech has arrived in Syremis Therapeutics. | Founded by a team of neuropsychiatric-focused Teva ...

As treatment for schizophrenia changes, LAIs are becoming increasingly important as maintenance therapy. Teva's pursuit of an ...

Neurocrine Biosciences ($NBIX) announced an update on their ongoing clinical study. Neurocrine Biosciences has announced the initiation of a Phase ...

Dual art therapy, combining music and painting, significantly improved symptoms, cognitive function, and quality of life in ...

For individuals diagnosed with schizophrenia, maintaining a daily medication routine can feel like an insurmountable challenge. The cognitive impairments associated with the disorder often interfere ...

On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the ...

Schizophrenia is the classic psychotic disorder and has long been considered the most severe form of mental illness. It is a problem that afflicts roughly 1 out of 100 people around the world. Since ...

A 33-year-old woman hears brutal and frightening voices daily but continues her college studies. A middle-aged man, who served in the Navy and has since struggled with substance abuse, spends 10 weeks ...

Shares in Tokyo-listed Nxera Pharma slid 5% at market open after Boehringer walked away from the neurological assets.

Neurocrine Biosciences Inc. plunged early Wednesday after a study of its experimental schizophrenia treatment was disappointing when compared to a rival medicine that’s likely to hit the market much ...